Globally, the ophthalmic drugs market is witnessing significant growth due to increasing prevalence of eye disorders such as diabetic retinopathy and macular degeneration. As a result, this market is expected to grow at a CAGR of about 5.2% during 2013 – 2018.
Albany, NY -- (SBWIRE) -- 08/19/2016 -- The ophthalmic drugs market is primarily driven by growing prevalence of eye disorders, especially among the geriatric population. The research report identifies and tracks the various forces that govern the ophthalmic drugs market and analyzes their impact on the global and regional market.
The report studies demand and supply trends affecting the numerous segments of the ophthalmic drugs market. Along with a detailed segmentation of products, applications, and geographical regions, the research report also offers accurate historic, current and projection figures of the worldwide ophthalmic drugs market.
With the help of market research tools such as Porter's five forces, SWOT analysis, value chain, and market attractiveness analysis, the report assesses the power and role of various elements within the ophthalmic drugs market such as buyers, suppliers, new entrants, and substitutes.
Complete Report with TOC @ http://www.mrrse.com/ophthalmic-drugs-market
Overview of the global ophthalmic drugs market
The ophthalmic drugs market can be segmented on the basis of geography and treatment drugs. Geographically, the ophthalmic drugs market is divided into North America, Europe, Asia-Pacific, and Rest of the World. North America leads the global ophthalmic drugs market, followed by Europe, owing to the increasing support from the government, technological advances, and presence of major industry participants. Asia-Pacific is one of the key markets for ophthalmic drugs due to growing patient pool, increase in healthcare expenditure, and infrastructure in emerging economies such as China and India, and rising disposable income.
On the basis of treatment drugs, the ophthalmic drugs market is segmented into retinal drugs, dry eye drugs, anti-glaucoma drugs, and ophthalmic inflammatory/anti-allergy/infective drugs. Of these, the anti-glaucoma drugs segment dominated the ophthalmic drugs market in terms of treatment drugs and is projected to register the highest growth rate during the forecast period.
Factors that restrain the growth of the ophthalmic drugs market include absence of healthcare insurance in developing countries, waning number of pipeline ophthalmic drugs, lack of awareness regarding eye disorders, and patent expiration of major ophthalmic drugs.
According to the report, the global ophthalmic drugs market and is expected to grow at a CAGR of 5.2% during 2013 to 2018 period.
Request a Free Sample Copy of the Report @ http://www.mrrse.com/sample/884
Companies mentioned in the research report
The report on the global ophthalmic drugs market offers a detailed evaluation of the competitive landscape. Identifying and assessing prominent participants of the ophthalmic drugs market, the report provides in-depth insights on the competitors in terms of company overview, financial standing, product portfolio, recent developments, trends, company size and volume, industry share and contribution, and SWOT analysis. Some of the leading vendors in the ophthalmic drugs market include Santen Pharmaceutical Co. Ltd., Roche Holding AG, Merck & Co. Inc., Allergan Inc., Pfizer Inc., and Novartis International AG.
MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.